Barriers to Molecular Research in Gliomas: Implications for Precision Medicine
Overview
Expand to specify the WHO classifications and their direct impact on glioma diagnostics.
Background
CNS tumors, particularly gliomas, pose significant diagnostic challenges due to their heterogeneity and the evolving WHO classification criteria. The integration of molecular markers into these classifications aims to enhance diagnostic accuracy and guide personalized treatment. However, in low- and middle-income countries, the lack of access to molecular testing creates barriers that prevent the effective application of these advanced diagnostic criteria.
Data Highlights
WHO Classification
Common Findings
2007
Virtually all tumors classified histologically
2016
Increased NOS cases and incomplete tumor characterization
2021
24% categorized as high- or low-grade glioma NOS
Key Findings
WHO 2007 criteria allowed for comprehensive histological classification of gliomas.
Implementation of WHO 2016 led to a rise in tumors labeled as 'not otherwise specified' (NOS).
Under WHO 2021, 24% of tumors remained inadequately characterized as glioma NOS.
Access to molecular testing is crucial for accurate glioma classification and treatment planning.
Resource limitations in low- and middle-income countries hinder the application of advanced WHO classification criteria.
Clinical Implications
Healthcare professionals in resource-limited settings must recognize the challenges posed by inadequate molecular testing capabilities. Efforts should be made to improve access to molecular diagnostics to enhance glioma classification and treatment outcomes.
Conclusion
The findings underscore the need for improved access to molecular testing in low- and middle-income countries to fully realize the benefits of updated WHO glioma classifications.
by Pablo S. Paolinelli, Tomas Saavedra Azcona, Florencia B. Casto, Ezequiel Jungberg, Nicolás Tilano, William A. Blettler, Joan S. Pazos, Silvina Dell’Era, Clara Lynch, Miguel Villaescusa, Pedro Plou, Pablo Ajler
